ProQR Therapeutics (PRQR) Share-based Compensation (2013 - 2026)

ProQR Therapeutics has reported Share-based Compensation for 14 years, with the latest figure at $1.7 million in Q1 2026.

• Quarterly Share-based Compensation rose 109.68% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 97.57% YoY) and the FY2025 annual result came in at $4.7 million, up 71.88% from the prior year.
• Share-based Compensation improved to $1.7 million in Q1 2026 per PRQR's latest filing, from $1.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $1.7 million in Q1 2026 and troughed at -$394835.7 in Q4 2022.
• A 5-year average of $906566.5 and a median of $833027.2 in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation sank 119.38% in 2022, then jumped 318.55% in 2023.
• Over 5 years, Share-based Compensation stood at -$394835.7 in 2022, then surged by 318.55% to $862903.8 in 2023, then dropped by 29.66% to $606962.2 in 2024, then soared by 135.89% to $1.4 million in 2025, then grew by 16.77% to $1.7 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.7 million, $1.4 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.